Drug intelligence / Profile preview

NS-025

Development stage: Unknown
Lead developer: Nippon Shinyaku
Administration: Ophthalmic, Intravitreal

Overview

NS-025 is an investigational drug candidate being developed by Nippon Shinyaku Co., Ltd. for the treatment of urological (urogenital) diseases. As of early 2024, the compound is in Phase 1 clinical development in Japan. Nippon Shinyaku has not yet publicly disclosed the specific biological target, mechanism of action, or modality (e.g., small molecule or biologic) for NS-025. The drug is part of the company's strategic focus on urology, which is one of its core therapeutic areas alongside hematology and rare diseases.

Beyond the preview

Go deeper on NS-025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NS-025.

Explore the full profile